摘要
目的探讨阿托伐他汀钙片对心绞痛患者血清可溶性CD40配体（CD40L）与高敏C反应蛋白（hsCRP）的干预作用。方法65例冠心病患者，其中稳定型心绞痛患者30例（SA组），小稳定型心绞痛患者35例（UA组），所有患者于入院当天清晨、治疗后2、4、6周静脉血，测定血清hsCRP、血清可溶性CD40L水平，并对两组结果进行比较。结果治疗前uA组血清可溶性CD40L、hs—CRP浓度分别为（20．52±2．91）μg／L、（7．96±1．69）mg／L，明显高于SA组（7．96±1．35）μg／L、（1．58±0．91）mg／L（t＝21．705、18．493，均P〈0．05），而两组治疗后血清可溶性CD40L、hs—CRP浓度均较治疗前明显降低（均P〈0．01）。结论血清可溶性CD40L、hsCRP参与了不稳定型心绞痛的病理生理过程，可以作为反映易损斑块的指标，阿托伐他汀钙片可通过降低血清可溶性CD40L、hs—CRP而加强粥样硬化斑块的稳定性。
Objective To investigate the intervention of level of atorvastatin calcium tablets （lipitor） on soluble CD40 （CD40L） and high sensitivity C reactive protein （hs CRP） in patients with angina. Methods 65 patients with coronary heart disease were divided into stable angina （SA group, n=30） and unstable angina （UA group, n= 35）. The vein blood was collected in the hospitalized morning, 2, 4, 6 weeks after treatment and serum levels of hs CRP and CD40L were measured and compared between the two groups. Results The levels of soluable CD40L [（20.52±2.91）μg/L and CRP [（7.96±1.69）mg/L] in UA group were higher than SA group [（7.96±1.35）μg/L] and （1.58±0.91） mg/L]（t= 21.705,18.493, both P〈0.05） before treatment, and after treatment, their levels in the two groups were significantly lower than pre treatment （P〈0.01）. Conclusions CD40L and hs CRP may involved in the pathophysiology of unstable angina process and can be used as an indicator reflecting vulnerable plaque. Lipitor might enhance stability of atherosclerotic plaque and prevent acute coronary events by reducing levels of CD40L and hs-CRP.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2011年第11期938-940,共3页
Chinese Journal of Geriatrics
